# Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

> **NCT07172347** · PHASE2 · RECRUITING · sponsor: **Jiangsu vcare pharmaceutical technology co., LTD** · enrollment: 120 (estimated)

## Conditions studied

- Non-segmental Vitiligo

## Interventions

- **DRUG:** VC005 tablets
- **DRUG:** VC005 Tablets Placebo

## Key facts

- **NCT ID:** NCT07172347
- **Lead sponsor:** Jiangsu vcare pharmaceutical technology co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-31
- **Primary completion:** 2027-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172347, "Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07172347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*